There are significant limitations in the current options for imaging of patients with prostate carcinoma. Although fluorodeoxyglucose is the mainstay of clinical imaging, many other isotope and tracer combinations can be imaged with PET. One of the strengths of nuclear imaging lies in the variety of radiotracers capable of being imaged. In the last 15 years, various compounds have been studied in the hope of identifying the ideal imaging agent for prostate cancer. In this article, the use of imaging agents other than fluorodeoxyglucose, choline, and acetate is discussed.
- Androgen receptors
- Prostate cancer
- Testosterone derivatives
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging